Table 1 Characteristics of groups
Study group | No further therapy | Only additional IAC | Systemic therapy | Biologic therapy | |
|---|---|---|---|---|---|
Number % (n) | 109 | 38.5% (42) | 15.5% [17] | 45.9% (49 MTX, 1 SSZ) | 22.0% (24) |
Age (years) | 8.0 (1.2–18.3) | 9.2 (1.2–18) | 6.9 (1.5–13.5) | 7.1 (1.5–18.3) | 7.7 years (1.8–18) |
ANA + | 38% (41) | 26.8% (11) | 29.5% (5) | 48% (24) | 54% (13) |
HLA B27 + | 14% (15) | 7.5% (3) | 17.6% (3) | 18% (9) | 25% (6) |
First IAC: - 1 joint - 2 joints - 3 joints | 76% (83) 22% (24) 2% (2) | 83% (35) 14.2% (6) 2% (1) | 70.6% (12) 39.4% (5) / | 74%(36) 24% (12) 2% (1) | 54% (13) 42% (10) 4% (1) |
Mean follow-up | 4.3 yrs (7 mo – 8.2 yrs) | 3.3 yrs (7 mo – 7.8 yrs) | 4.7 yrs (1.4–6.7) | 5.1 yrs (1.4–8.1) | 5.2 yrs (1.4–8.1) |
Inactive disease at last follow-up visit | 88.9% (97) | 100% | 100% | 74% (36) | 75% (18) |
Remission off therapy at last follow-up visit | 70.6% (77) | 100% | 100% | 44% [16] | 11% [2] |